| GC33754-1mg |
|
106447-61-4 |
|
0 |
C17H15N5O2 |
|
|
|
| GC33753-1g |
|
621-59-0 |
Isovanillin (3-Hydroxy-4-methoxybenzaldehyde)
|
0 |
C8H8O3 |
|
|
|
| GC33753-10mM(1mLinDMSO) |
|
621-59-0 |
Isovanillin (3-Hydroxy-4-methoxybenzaldehyde)
|
0 |
C8H8O3 |
|
|
|
| GC33752-20mg |
|
97627-24-2 |
N-(2-Chloro-6-methylphenyl)-N’-4-pyridinylurea
|
0 |
C13H12ClN3O |
|
|
|
| GC33752-10mg |
|
97627-24-2 |
N-(2-Chloro-6-methylphenyl)-N’-4-pyridinylurea
|
0 |
C13H12ClN3O |
|
|
|
| GC33752-5mg |
|
97627-24-2 |
N-(2-Chloro-6-methylphenyl)-N’-4-pyridinylurea
|
0 |
C13H12ClN3O |
|
|
|
| GC33752-1mg |
|
97627-24-2 |
N-(2-Chloro-6-methylphenyl)-N’-4-pyridinylurea
|
0 |
C13H12ClN3O |
|
|
|
| GC33751-20mg |
|
64078-09-7 |
|
0 |
C21H21Cl2N5O2 |
|
|
|
| GC33751-10mg |
|
64078-09-7 |
|
0 |
C21H21Cl2N5O2 |
|
|
|
| GC33751-5mg |
|
64078-09-7 |
|
0 |
C21H21Cl2N5O2 |
|
|
|
| GC33751-1mg |
|
64078-09-7 |
|
0 |
C21H21Cl2N5O2 |
|
|
|
| GC33749-100mg |
|
5784-74-7 |
Salsolidine (6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline)
|
0 |
C12H17NO2 |
|
|
|
| GC33749-50mg |
|
5784-74-7 |
Salsolidine (6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline)
|
0 |
C12H17NO2 |
|
|
|
| GC33749-25mg |
|
5784-74-7 |
Salsolidine (6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline)
|
0 |
C12H17NO2 |
|
|
|
| GC33749-10mM(1mLinDMSO) |
|
5784-74-7 |
Salsolidine (6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline)
|
0 |
C12H17NO2 |
|
|
|
| GC33748-1g |
|
601-75-2 |
|
0 |
C5H8O4 |
|
|
|
| GC33747-10mg |
|
168266-90-8 |
|
0 |
C21H23F3N6O |
|
|
|
| GC33747-5mg |
|
168266-90-8 |
|
0 |
C21H23F3N6O |
|
|
|
| GC33746-50mg |
|
490-83-5 |
|
0 |
C6H6O6 |
|
|
|
| GC33745-20mg |
|
357336-17-5 |
Anticonvulsant agent 1 (4-(2,2-Difluoroethenyl)-α-ethyl-2-oxo-1-pyrrolidineacetamide)
|
0 |
C10H14F2N2O2 |
|
|
|
